24195-07-1

Basic information

• Product Name: quinolinic acid, 2-methyl ester
• Synonyms: quinolinic acid, 2-methyl ester;2-(methoxycarbonyl)nicotinic acid;2-Methoxycarbonylpyridine-3-carboxylic acid;2,3-Pyridinedicarboxylic acid, 2-methyl ester;2-carbomethoxynicotinic acid;2-methoxycarbonyl-3-pyridinecarboxylic acid;2-Methyl quinolinate;QA2ME
• CAS NO: 24195-07-1
• Molecular Formula: C₈H₇NO₄
• Molecular Weight: 181.15
• Product Categories: Esters;Pyridines
• Mol File: 24195-07-1.mol
• Article Data: 18

Chemical Properties

• Melting Point: 54-55 °C
• Boiling Point: 380.7°Cat760mmHg
• Flash Point: 184.1°C
• Appearance: /
• Density: 1.361g/cm³
• Vapor Pressure: 1.78E-06mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: Room temperature.
• PKA: 2.59±0.10(Predicted)
• CAS DataBase Reference: quinolinic acid, 2-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: quinolinic acid, 2-methyl ester(24195-07-1)
• EPA Substance Registry System: quinolinic acid, 2-methyl ester(24195-07-1)

Safety Data

• Hazardous Substances Data: 24195-07-1(Hazardous Substances Data)

Usage

General Description

Quinolinic acid, 2-methyl ester is a chemical compound that is derived from quinolinic acid, which is a byproduct of the kynurenine pathway in the body. It is a neuroactive compound that has been implicated in various neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. The 2-methyl ester derivative of quinolinic acid has been studied for its potential role as a biomarker for these conditions, as well as for its potential therapeutic applications. Additionally, it has been investigated for its activity in the central nervous system and its potential involvement in neuroinflammation and excitotoxicity. Further research is needed to fully understand the impact of quinolinic acid, 2-methyl ester on neurological function and its potential as a target for therapeutic intervention in various neurological disorders.

InChI:InChI=1/C8H7NO4/c1-13-8(12)6-5(7(10)11)3-2-4-9-6/h2-4H,1H3,(H,10,11)

Upstream product

• 24195-02-6 pyridine-2,3-dicarboxylic acid 3-methyl ester 
• 141-78-6 ethyl acetate 
• 78-92-2 iso-butanol 
• 67-56-1 methanol 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 
• 699-98-9 Pyridine-2,3-dicarboxylic anhydride 
• 605-38-9 dimethyl 2,3-pyridinedicarboxylate 
• 124-41-4 sodium methylate 

Downstream Products

• 100872-65-9 2-[[(phenylmethyl)amino]carbonyl]-3-pyridinecarboxylic acid 
• 100616-13-5 2-cyclohexylcarbamoyl-nicotinic acid 
• 93-60-7 methyl 3-pyridinecarboxylate 
• 5657-51-2 7H-furo[3,4-b]pyridin-5-one 
• 81334-34-1 2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)nicotinic acid 
• 18184-75-3 6-benzyl-5H-pyrrolo[3,4-b]pyridine-5,7(6H)-dione 
• 102554-68-7 6-(1,1-diphenylmethyl)-5H-pyrrolo[3,4-b]pyridine-5,7-dione 
• 6538-81-4 6-Phenylpyrrolo<3,4-b>pyridine-5,7(6H)-dione 
• 1393687-15-4 C₁₇H₁₈N₂O₃ 

Relevant articles and documents

SYNTHESIS OF A SICKLE CELL DISEASE AGENT AND INTERMEDIATES THEREOF

New processes for preparing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5- yl)pyridin-3-yl)methoxy)benzaldehyde, an agent developed for the treatment of sickle cell disease, and intermediates thereof, are provided herein.

IDO/TDO Inhibitor

A compound of formula (I) given below or a pharmaceutically acceptable salt of the compound is useful as an IDO/TDO inhibitor. Thus, the compound of formula (I) or the pharmaceutically acceptable salt of the compound can be used as, for example, a therapeutic agent for a disease or a disorder selected from tumor, infectious disease, neurodegenerative disorder, cataract, organ transplant rejection, autoimmune disease, postoperative cognitive impairment, and disease related to women's reproductive health [in the following formula (I), ring A represents an aromatic ring, an aliphatic ring, a heterocyclic ring, or a condensed ring of two or more rings selected from an aromatic ring, an aliphatic ring and a heterocyclic ring; X, R1 and R2 represent a substituent on a ring atom constituting ring A; m represents an integer of 0 to 6; X represents, for example, a halogen atom; and R1 and R2 are the same or different and are selected from, for example, the group consisting of groups of formula (a) or formula (b); and in the following formula (a) and formula (b), Y is selected from the group consisting of O, S, and Se, Z is selected from the group consisting of O, S, and Se, n represents an integer of 1 to 8, r represents an integer of 1 to 8, s represents an integer of 1 to 8, R4 represents, for example, —C(═NH)—HN2, and R6 represents, for example, a substituted or unsubstituted aryl group].

Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase i Poisons

Several indenoisoquinolines have shown promise as anticancer agents in clinical trials. Incorporation of a nitrogen atom into the indenoisoquinoline scaffold offers the possibility of favorably modulating ligand-binding site interactions, physicochemical properties, and biological activities. Four series of aza-A-ring indenoisoquinolines were synthesized in which the nitrogen atom was systematically rotated through positions 1, 2, 3, and 4. The resulting compounds were tested to establish the optimal nitrogen position for topoisomerase IB (Top1) enzyme poisoning activity and cytotoxicity to human cancer cells. The 4-aza compounds were the most likely to yield derivatives with high Top1 inhibitory activity. However, the relationship between structure and cytotoxicity was more complicated since the potency was influenced strongly by the side chains on the lactam nitrogen. The most cytotoxic azaindenoisoquinolines 45 and 46 had nitrogen in the 2- or 3-positions and a 3′-dimethylaminopropyl side chain, and they had MGM GI50 values that were slightly better than the corresponding indenoisoquinoline 64.